Small Pharma Inc.
DMTTF · OTC
5/31/2023 | 2/28/2023 | 11/30/2022 | 8/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.05 | 0.28 | -0.12 |
| FCF Yield | -25.83% | -15.40% | -17.23% | -5.85% |
| EV / EBITDA | -1.75 | -2.78 | -1.17 | -10.14 |
| Quality | ||||
| ROIC | -44.86% | -13.35% | -37.63% | -29.83% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 1.92 | 0.75 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -26.12% | 14.81% | 10.66% | 4.99% |
| Safety | ||||
| Net Debt / EBITDA | 2.27 | 4.24 | 3.19 | 3.64 |
| Interest Coverage | -739.36 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |